Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
暂无分享，去创建一个
A. Shaw | S. Peters | E. Felip | B. Solomon | S. Gadgeel | Chia‐Chi Lin | A. Abbattista | B. Besse | R. Soo | S. Kao | T. Seto | A. Bearz | A. Reisman | J. Clancy | E. Masters | G. Peltz | H. Thurm | D. Ross Camidge